MorphoSys AG (MOR) 2020年年度报告「NASDAQ」.pdf

1、Annual ReportAnnual Report 2020Our Clinical PipelineClinical Programs Developed by Partners(Selection)Most advanced development stageProgram/Partner IndicationTremfya(guselkumab)/Janssen/J&J Psoriasis Felzartamab(MOR202)1/I-Mab Multiple myeloma Otilimab(MOR103/GSK3196165)/GlaxoSmithKline Rheumatoid

2、arthritis Severe pulmonary COVID-19 related disease Gantenerumab/Roche Alzheimers disease Anetumab ravtansine(BAY94-9343)/Bayer Solid tumors Ianalumab(VAY736)/Novartis Inflammation MAA868/Anthos Therapeutics Atrial fibrillation Most advanced development stageProgram IndicationTafasitamab(MOR208)1 L-

3、MIND/Relapsed or refractory(r/r)diffuse large B-cell lymphoma(DLBCL)B-MIND/r/r DLBCL firstMIND/First-line DLBCL frontMIND/First-line DLBCL inMIND/r/r follicular lymphoma/marginal zone lymphoma Felzartamab(MOR202)M-PLACE/Anti-PLA2R-positive membranous nephropathyNew-PLACE/Anti-PLA2R-positive membrano

4、us nephropathy Most advanced development stageProgram/Partner IndicationNOV-8(CMK389)/Novartis Pulmonary sarcoidosis NOV-9(LKA651)/Novartis Diabetic eye diseases Setrusumab(BPS804)/Mereo/Novartis/Ultragenyx Brittle bone syndrome Utomilumab(PF-05082566)/Pfizer Solid tumors Xentuzumab(BI-836845)/BI So

5、lid tumors NOV-14(CSJ117)/Novartis Asthma MOR2102/I-Mab r/r advanced solid tumors MorphoSys,March 2021PHASE 1PHASE 2PHASE 3LAUNCHEDPHASE 1PHASE 2PHASE 3LAUNCHEDPHASE 1PHASE 2PHASE 3LAUNCHED1 Global Collaboration and License Agreement with Incyte Corporation;co-commer-cialization in the U.S.;Incyte h

6、as exclusive commercialization rights outside the U.S.2 Not conducted,as not necessary.Pipeline products are under clinical investigation and there is no guarantee any investigational product will be approved byregulatory authorities.1 Sublicensed to I-Mab for development in China,Hong Kong,Macao an